- Home
- ASRT vs XFOR Comparison
ASRT vs XFOR Comparison
Compare ASRT & XFOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ASRT | XFOR |
|---|---|---|
| Founded | 1995 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 75.1M | 324.4M |
| IPO Year | 1997 | N/A |
Fundamental Metrics
Financial Performance| Metric | ASRT | XFOR |
|---|---|---|
| Price | $9.94 | $4.50 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $45.00 | $28.50 |
| AVG Volume (30 Days) | 30.2K | ★ 940.0K |
| Earning Date | 11-10-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $137,354,000.00 | $33,979,000.00 |
| Revenue This Year | N/A | $1,276.65 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 9.22 | ★ 2925.74 |
| 52 Week Low | $7.71 | $1.35 |
| 52 Week High | $15.15 | $26.83 |
Technical Indicators
Market Signals| Indicator | ASRT | XFOR |
|---|---|---|
| Relative Strength Index (RSI) | 98.16 | 64.68 |
| Support Level | $0.61 | $3.50 |
| Resistance Level | $0.75 | $4.56 |
| Average True Range (ATR) | 0.10 | 0.31 |
| MACD | 0.58 | 0.07 |
| Stochastic Oscillator | 94.90 | 85.12 |
Price Performance
Historical ComparisonAbout ASRT Assertio Holdings Inc.
Assertio Holdings Inc is a pharmaceutical company. It is engaged in providing solutions to advance patient care in the areas of neurology, orphan and specialty medicines. The company markets three FDA-approved products for various neurological conditions including Gralise, tablets for the management of postherpetic neuralgia; CAMBIA, for acute treatment of migraine attacks with or without aura in adults of age or older and Zipsor, liquid-filled capsules for relief of mild to moderate pain.
About XFOR X4 Pharmaceuticals Inc.
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare diseases of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.